Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) said its Board authorized a quarterly cash dividend of $0.47 per common share, payable April 15, 2026 to shareholders of record as of March 13, 2026. This represents a 10% increase from the prior quarterly dividend of $0.43.
Thermo Fisher Scientific (NYSE: TMO) said Marc N. Casper, chairman, president and CEO, will present at the Raymond James Institutional Investors Conference on March 3, 2026 at 9:15 a.m. ET. A live webcast will be available in the company's Investors section, with a replay accessible shortly after the presentation.
Thermo Fisher (NYSE: TMO) priced a $3.8 billion offering of USD-denominated senior notes across four maturities: $1.0B 4.215% due 2031, $750M 4.550% due 2033, $1.3B 4.902% due 2036, and $750M 5.546% due 2046.
The offering is expected to close on or about February 12, 2026, with semi-annual interest. Net proceeds are intended to pay part of the cash consideration for the pending Clario acquisition or for general corporate purposes pending closing.
Thermo Fisher Scientific (NYSE: TMO) reported Q4 2025 revenue of $12.21B (up 7%) and full-year 2025 revenue of $44.56B (up 4%).
GAAP diluted EPS was $5.21 for Q4 and $17.74 for the year; adjusted EPS was $6.57 Q4 and $22.87 for 2025. The company deployed $16.5B of capital in 2025, including $13B for M&A and returned $3.6B to shareholders.
Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with NVIDIA on January 12, 2026 to integrate NVIDIA AI infrastructure into Thermo Fisher instruments and lab software.
The partnership will use NVIDIA DGX Spark, NVIDIA NeMo and NVIDIA BioNeMo to add AI-driven automation, improve accuracy and speed workflows, connect instruments and data to AI models, and advance autonomous or “lab-in-the-loop” scientific workflows that aim to reduce manual steps and accelerate research.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.
Thermo Fisher Scientific (NYSE:TMO) announced that Marc N. Casper, chairman, president and CEO, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026 at 11:15 a.m. ET.
A live webcast will be available in the company's Investors section at www.thermofisher.com, with a replay accessible shortly after the presentation concludes.
Thermo Fisher Scientific (NYSE: TMO) will release its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, January 29, 2026. The company will hold a conference call the same day at 8:30 a.m. ET to discuss financial performance and future expectations.
The call will be webcast live in the Investors section of www.thermofisher.com. U.S. dial-in is (833) 470-1428; international dial-in is +1 (646) 844-6383; access code 054943. The earnings release and related materials will appear under Financials, and a replay will be available under News, Events & Presentations through Wednesday, April 22, 2026.
OlivePoint Capital and Redwood Capital acquired 3900 Paramount Parkway, a 220,000-square-foot Class A office building in Research Triangle Park, Raleigh–Durham, on December 15, 2025. The property is 100% leased to Pharmaceutical Product Development (PPD), a subsidiary of Thermo Fisher Scientific (NYSE: TMO), backed by long lease duration and corporate credit support.
The buyers said they purchased the asset at a discount to replacement cost and at an attractive in-place yield, citing office-sector dislocation as a sourcing opportunity and RTP’s strong tenant demand driven by life sciences and tech.
Thermo Fisher Scientific (NYSE:TMO) announced on December 2, 2025 an expansion of its Bioprocess Design Center network across Asia with a new center in Hyderabad, India and enlarged centers in Incheon, Korea and Singapore. The tri-hub network aims to provide localized expertise, bench-to-pilot capabilities, single-use and hybrid systems, and collaborative spaces to accelerate process development, training and scale-up for biologics, vaccines and cell and gene therapies.
The company said the expansion supports faster, more cost-effective and more sustainable biomanufacturing across Asia and was developed in partnership with the Government of Telangana for the Hyderabad site.